% | $
Quotes you view appear here for quick access.

Gilead Sciences Inc. Message Board

  • carolyn_novice carolyn_novice Sep 12, 2013 10:49 PM Flag

    Fidelity Select Biotechnology FBIOX GILD 63.19

    Fidelity Select Biotechnology FBIOX GILD 63.10

    Mergers and acquisitions as well as new treatments have been the big drivers in biotech, says Loo. And there have been several high-profile approvals by the FDA.
    Biotech also got a boost in the second quarter as several companies increased guidance on their top and bottom lines.

    Managed care has soared after a slow start this year. The turnaround was sparked by the Centers for Medicare & Medicaid Services' April 1 approval of rate hikes for Medicare Advantage.

    Drugmakers have moved sideways since investors began to pull back from dividend-paying stocks sensitive to interest-rate hikes.

    Gilead Sciences' (GILD) three-drug pill for HIV still enjoys patent protection. Also, Gilead's new hepatitis C drug, sofosbuvir, should drive earnings for the next five years, says Evan McCulloch, lead manager of $970 million Franklin Biotechnology Discovery.

    Not Done
    Also, Gilead has made several acquisitions in hematology. "They're probably not done," he said.
    Source :IBD

    Investing in Biotech results in GILD

    Fidelity Select Biotechnology Portfolio FBIOX

    Security ------------------------ Net Assets
    Gilead Sciences Inc(GILD) ------------------------ 14.48%
    Amgen Inc(AMGN) ------------------------ 11.40%
    Celgene Corporation(CELG) ------------------------ 7.43%
    Biogen Idec Inc(BIIB) ------------------------ 5.99%
    Alexion Pharmaceuticals, Inc.(ALXN) ------------------------ 4.35%
    Regeneron Pharmaceuticals, Inc.(REGN) ------------------------ 3.91%
    Vertex Pharmaceuticals(VRTX) ------------------------ 3.61%
    Aegerion Pharmaceuticals, Inc.(AEGR) ------------------------ 2.76%
    Onyx Pharmaceuticals, Inc.(ONXX) ------------------------ 2.43%
    Pharmacyclics, Inc.(PCYC) ------------------------ 2.23%


    Carolyn Novice

97.00-3.72(-3.69%)Apr 28 4:00 PMEDT